Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.93 USD
+0.16 (9.04%)
Updated May 13, 2024 04:00 PM ET
After-Market: $1.93 0.00 (0.00%) 7:04 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.93 USD
+0.16 (9.04%)
Updated May 13, 2024 04:00 PM ET
After-Market: $1.93 0.00 (0.00%) 7:04 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Zacks News
Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock
by Zacks Equity Research
Pacific Biosciences (PACB) needs investors to pay close attention to the stock based on moves in the options market lately.
What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?
by Zacks Equity Research
Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.
Pacific Biosciences Hurt by Competition in Niche Markets
by Zacks Equity Research
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated
by Zacks Equity Research
Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.
Pacific Biosciences, Bluebee Team Up for De Novo Sequencing
by Zacks Equity Research
With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.
Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.
Pacific Biosciences (PACB) Prices Offering of Common Stock
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB) recently announced that it has priced its underwritten public offering of 15.4 million shares of its common stock.
Pacific Biosciences (PACB) Q1 Loss Wider than Estimated
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB) reported a loss of 26 cents per share in the first quarter of 2017. The figure is 3 cents wider than the Zacks Consensus Estimate.
Pacific Biosciences (PACB): What Awaits in Q1 Earnings?
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB) is scheduled to report first-quarter 2017 results on Apr 20.
Pacific Biosciences (PACB) Up 5.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.
Pacific Biosciences (PACB): What Awaits in Q4 Earnings?
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB) is scheduled to report fourth-quarter 2016 results on Feb 1, 2017.
Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB), announced that it will sell 10 PacBio Sequel Systems to Novogene Bioinformatics Technology Company, Ltd.
Pacific Biosciences Terminates SMRT Agreement with Roche
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB), announced that F. Hoffman-La Roche Ltd has chosen to terminate a preexisting development, commercialization and license agreement.